Novo Nordisk's reports to the FDA spiked shortly after an inspection found the Ozempic producer ignored reports of deaths and potential side effects.

Some less common but serious side effects of gabapentin include suicidal thoughts, allergic reactions, and serious breathing ...

A case series reports dysesthesia and allodynia in patients treated with semaglutide and tirzepatide, suggesting a possible dose related to sensory adverse effect.

Managing complex medical conditions often requires the simultaneous use of multiple different drugs, referred to as polypharmacy. While necessary, this significantly increases the risk of drug-drug ...

March 11 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has introduced a unified platform designed to ...

Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University.

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster ...

Drug-drug interactions (DDI) can cause adverse drug reactions during the co-administration of multiple drugs, necessitating accurate and scalable prediction tools. While deep learning models have ...

Female cancer patients have increased survival but also have a higher risk for serious and adverse side effects from cancer treatment compared with men, according to a study published online Feb. 16 ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and ...

A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4 ...

Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) on behalf of investors that purchased or ...